[嵌合抗原受体T细胞免疫疗法，一个监管里程碑]

[CAR-T immunotherapy, a regulatory milestone].

作者信息

Jordan Bertrand

机构信息

UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ; CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.

出版信息

Med Sci (Paris). 2017 Nov;33(11):1003-1006. doi: 10.1051/medsci/20173311020. Epub 2017 Dec 4.

DOI:10.1051/medsci/20173311020

PMID:29200401

Abstract

The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term remission approaching a cure). In spite of their complexity and cost, CAR-T therapies will probably end up playing a very significant role in cancer therapy.

摘要

首个基于嵌合抗原受体的疗法已获美国食品药品监督管理局（FDA）批准。它在复发性儿童急性淋巴细胞白血病（ALL）中疗效显著；其成本非常高，但与临床获益（接近治愈的长期缓解）相当契合。尽管嵌合抗原受体T细胞（CAR-T）疗法复杂且成本高昂，但它们最终可能会在癌症治疗中发挥非常重要的作用。